Abstract 3207
Background
Glioblastoma, the most common primary brain tumour in adults, universally recurs with dismal prognosis. To date, clinical trials with protein kinase inhibitors (PKIs) failed to demonstrate efficacy in glioblastoma, possibly due to the blood-brain barrier, which may prevent adequate drug accumulation in the tumour. However, in a pilot study we demonstrated that tumour concentrations of sunitinib, a multi-receptor PKI, in patients with newly-diagnosed glioblastoma are within the range of tumour concentrations measured in metastases from patients with other solid tumours (NCT02239952). In addition, we demonstrated in a phase I/II study that an alternative schedule of high-dose, intermittent sunitinib, aiming at high intratumoral peak concentrations, was feasible, safe and showed promising antitumor activity in patients with refractory solid tumours (JCO; PMID 30586316). These results indicate that drug resistance can be overcome by an alternative, chemotherapy-like schedule of intermittent and high-dosed sunitinib, administered once weekly or once every two weeks. Therefore, we initiated a randomized, phase II/III clinical trial with high-dose, intermittent sunitinib designed to achieve adequate tumour concentrations in patients with glioblastoma, aiming for significant clinical benefit compared to treatment with lomustine.
Trial design
Adult patients with first progression of de novo or secondary glioblastoma after first-line treatment are included in this randomized, phase II/III, multi-centre, open-label clinical trial. The primary endpoint is the six-month progression-free survival of treatment with high-dose sunitinib versus lomustine. Hundred patients will be randomized to receive either sunitinib 300 mg, administered orally once every week or lomustine 110 mg/m2, administered orally on day 1 every 6 weeks. Response evaluation will be assessed by MRI every 6 weeks for the first 6 months, and every 12 weeks until documented progression. Secondary endpoints include safety and quality of life assessments. An interim analysis will be performed after inclusion of 25 patients. As of May 2019, 16 patients have been enrolled.
Clinical trial identification
NCT03025893.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Labots: Advisory / Consultancy: Bristol-Myers Squibb. A.M.E. Walenkamp: Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy, Research grant / Funding (self): Ipsen. H.M.W. Verheul: Advisory / Consultancy, Research grant / Funding (self): Roche; Advisory / Consultancy, Research grant / Funding (self): Glycostem; Research grant / Funding (self): Immunovo. All other authors have declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract